Drugs / sodium polysulthionate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02278276 Comparator | Apr 2016 → Apr 2018 | heart failure | Sulfagenix Australia Pty Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium polysulthionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02278276 ↗ |
| Known as | SG1002 | “Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects.” NCT02278276 ↗ |